MIAMI, Jan. 15, 2018 – Global Stem Cells Group,  a world leader in stem cell and regenerative medicine, will host its South American Regenerative Medicine Symposium August 23, 24, and 25th in Buenos Aires, Argentina. This will be GSCG’s fifth consecutive year hosting the symposium.

The main topic for the 2018 event is “Next Generation Medicine: Adult Stem Cells.”

Universidad de Buenos Aires

The symposium will again be hosted at the Faculty of Medicine of the Universidad de Buenos Aires, and will provide an opportunity to showcase advancements in adult stem cell research and therapies on a global level and establish a dialogue among some of the world’s leading stem cell experts. Ten international speakers will share their clinical experience improving the quality of patients’ lives using adult stem cell therapies.

According to Benito Novas, Global Stem Cells Group CEO, the symposium will showcase advances in adult stem cell research and therapies.

“This year’s symposium will highlight the strides stem cell research has made in adult stem cell applications,” Novas says. “

Since 2014, Global Stem Cells Group worked with some of the most prestigious regenerative medicine practitioners in South America as it focuses on growing its services throughout the global community. Stem cell therapies continue to revolutionize the healthcare industry while offering new hope for sufferers of chronic, debilitating conditions.

To learn more about the Fifth Annual South American Regenerative Medicine Symposium visit the Stem Cell Conference website,  email info@stemcellsgroup.com, or call 305-560-5337.

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global stem cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world.

 

 

 

 

 

 

Image: Benito Novas

 

Global Stem Cells Group founder and CEO Benito Novas was recognized as a leader in regenerative medicine at the XVIII International Congress of Aesthetic Medicine, Aesthetic Surgery and Obesity, Dec. 2, 2017, in Mexico City.

MIAMI, Dec. 22, 2017—Benito Novas, founder and CEO of Global Stem Cells Group (GSCG), earned recognition for his leadership in regenerative medicine at the XVIII International Congress of Aesthetic Medicine, Aesthetic Surgery and Obesity, Dec. 2, 2017, in Mexico City.

Novas accepted the recognition, signed and presented to him by Congress President Rector Doctor Arturo Conde at the event, honoring him for helping thousands of physicians around the world bring regenerative medicine therapies to their clinical practices.

Novas provided training and equipment to physicians throughout South America, North America, Europe, Asia, and the Middle East through GSCG affiliate companies Stem Cell Training, Adimarket online regenerative medicine store, and Stem Cell Center Network (present in more than 30 cities globally).

Novas is a global entrepreneur, manager, and keynote speaker with expertise in the field of specialized marketing focused on biotechnology, life sciences, and healthcare development.

The philosophy that has driven him to launch and grow his companies is the desire for a perpetual flow of knowledge and innovation with regard to the role of stem cells in modern medicine.

“My aim is to accelerate the process of getting promising stem cell research and technology developed into treatments and therapies, and to make them readily available to benefit the health and well-being of a broad range of patients,” he says.

Using specialized marketing techniques focused on stem cells and their impact on the field of aesthetic surgery, Novas created a multi-company corporation based on his visionary approach to healthcare management and regenerative medicine.

To learn more about Global Stem Cells Group, visit the company website, email info@stemcellsgroup.com, or call 305-560-5337.

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global Stem Cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world.

Benito Novas recognized

 

 

 

 

 

 

 

Adimarket, a subsidiary of Global Stem Cells Group, has announced an agreement with biotechnology company Alolotl Biologix to distribute biological products for regenerative medicine applications worldwide.

 MIAMI, Dec.21, 2017— Adimarket, a subsidiary of Global Stem Cells Group (GSCG), and its subsidiary has announced an agreement with Phoenix, Arizona-based Alolotl Biologix to distribute the biotechnology company’s products for regenerative medicine applications worldwide.

Alolotl Biologix focuses on research to optimize the use of human biologicals and to develop biological-related products to foster regeneration and healing for a range of conditions, including orthopedic impairments, wound care, pain management, ophthalmic, cardiovascular, cosmetic, and more.

Adimarket will make the following amniotic liquid products available to qualified practitioners through its online store www.adimarket.net:

AxoBioFluid® C Amniotic Allograft Cryopreserved Liquid, cryopreserved liquid allograft derived from the amniotic membrane that provides structural tissue to advance soft tissue repair, replacement, and reconstruction. Product details:

  • Human allograft under FDA regulation 21 CFR Part 1271 and section 361 of the PHS
  • Immune privileged with anti-inflammatory and anti-bacterial properties
  • A rich source of growth factors, proteins, cytokines, hyaluronic acid, and collagen scaffolds
  • Contains extracellular matrix components for cellular   attachment and proliferation
  • Cryopreserved for an extended shelf life

AxoBioFluid® physician benefits

  • Procedures are efficient and do not require special instrumentation.
    •  The use of AxoBioFluid® is billed as patient pays, which makes it a great alternative revenue source.
    •  A library of research papers to demonstrate efficacy degenerated tissue is provided.

AxoBioFluid® patient benefits

Relevant Conditions

AxoBioFluidâ C Amniotic Allograft Cryopreserved Liquid, cryopreserved liquid allograft derived from the amniotic membrane that provides structural tissue to advance soft tissue repair, replacement, and reconstruction. Product details:

  • Human allograft under FDA regulation 21 CFR Part 1271 and section 361 of the PHS
  • Immune privileged with anti-inflammatory and anti-bacterial properties
  • A rich source of growth factors, proteins, cytokines, hyaluronic acid, and collagen scaffolds
  • Contains extracellular matrix components for cellular   attachment and proliferation
  • Cryopreserved for an extended shelf life

AxoBioFluidâ physician benefits

  • Procedures are efficient and do not require special instrumentation.
    •  The use of AxoBioFluid® is billed as patient pays, which makes it a great alternative revenue source.
    •  A  library of research papers to demonstrate efficacy is provided.

AxoBioFluid® Amniotic Allograft Cryopreserved Liquid is a cryopreserved liquid allograft derived from the placental components of the amnion to advance soft tissue repair, replacement, and reconstruction. It is classified as minimally manipulated under FDA regulation 21 CFR Part 1271 and section 361 of the PHS. Benefits of AxoBioFluid® AxoBioFluid® is a human allograft fluid derived from the amniotic layer of the placenta. The two primary cell lines which reside in the amnion are human mesenchymal stromal cells (hMSC) and human amnion epithelial cells (hAEC). Both of these cells are considered to be pluripotent stem cells. AxoBioFluid® contains growth factors released while amniotic cells are grown in culture such as epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and transforming growth factor – beta (TGF-β). These proteins are essential for fetal growth and development and express significant therapeutic benefits when used as a treatment for various injuries and degenerative conditions. AxoBioFluid® is immuneprivileged, anti-inflammatory, anti-fibrotic, pro-vascular, and cytoprotective because of the cells being sourced from the amnion. These secreted factors also signal endogenous progenitor cells to promote regeneration and repair of damaged or degenerated tissue.

AxoBioFluid

  • Degenerative disorders such as osteoarthritis
    • Joint pain
    • Inflammatory conditions such as:
  • Bursitis
  • Tendonitis
  • Fasciitis
  • Epicondylitis
  • Soft tissue injuries such as:
  • Ligament & Tendon sprains
  • Muscle & Meniscus tears
  • Wound Care

AxoBioMembrane, a dehydrated allograft membrane patch derived from the amnion that advances wound repair, skin replacement, and reconstruction. Product details:

  • Human allograft under FDA regulation 21 CFR Part 1271 and section 361 of the PHS
  • Immune privileged with anti-inflammatory and anti-bacterial properties
  • Contains extracellular matrix components for cellular attachment and proliferation
  • Dehydrated and terminally e-beam sterilized for an extended shelf life.

AxoBioMembraneä Amniotic Allograft Membrane, like all allograft tissue products, has been subjected to recovery microbiological study and has been terminally sterilized with electron beam sterilization.  It works by forming fibrin-elastin bonds at the wound site, ensuring excellent wound adherence. This generates a barrier that protects exposed nerve endings from irritants, providing pain relief while creating a favorable environment for tissue repair and regeneration. In addition, the AxoBioMembrane™ prevents excessive moisture loss by creating a vapor barrier at the wound surface. Growth factors present in the membrane are released into the wound bed, promoting angiogenesis leading to new blood supply needed for cellular migration, proliferation and ultimately, wound repair. Infection is one of the biggest concerns with chronic wounds. AxoBioMembrane™ functions as a bacteriostatic agent, which can inhibit the growth of bacteria at the wound site and reduce the rate infection. It has also been reported to have anti-fibrotic properties, which can reduce scarring. The membrane contains glycoprtoteins found exclusively in the amnion. AxoBioMembrane™ lacks specific surface antigens, which make it immune-privileged and anti-inflammatory.

AxoBioMembraneä physician benefits

  • Procedures are efficient and do not require special instrumentation.
  • AxoBioMembrane™ is billed as patient pays, which makes it a great alternative revenue source.
  • We provide a library of research and white papers to demonstrate efficacy.

AxoBioMembraneä  patient benefits:

  • Pain Reduction
  • Wound Adherence
  • Less Scarring
  • Faster Healing
  • Neovascularization
  • Wound Barrier
  • Anti-bacterial
  • Immune Privileged

AxoBio products are available to purchase on the Adimarket Website.

For more information, visit the Adimarket regenerative medicine online store website, email info@stemcellsgroup.com, or call 305-560-5337.

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global stem cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world. 


About Adimarket:

Adimarket, Inc.,
a division of the Global Stem Cells Group, is a one-stop, cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals.

Adimarket was founded to provide practitioners the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting-edge treatments.

About Alolotl Biologix:
amniotic biofluid
Axolotl Biologix, Inc. is an innovative biotechnology leader in regenerative medicine through research, technology and clinical application. Axolotl Biologix is expanding the human body’s ability to regenerate by developing and manufacturing regenerative human cell and tissue, medical technologies that are disrupting traditional, more invasive, painful, and expensive treatment protocols. For more information, visit www.axobio.com.

###

 

amniotic biofluid

StemData relaunch

Global Stem Cells Group has announced the relaunch of its StemData cloud-based electronic medical record system specifically designed for regenerative medicine practitioners.

MIAMI, Nov. 29, 2017—Global Stem Cells Group, a world leader in stem cell and regenerative medicine, has announced the relaunch of its StemData software, the first cloud-based electronic medical record system specifically designed for regenerative medicine practitioners.

The StemData system, initially launched in September 2016, is a customized software program for physicians who operate a regenerative medicine practice. The StemData software empowers physicians to follow patients throughout their treatment schedules. The StemData program comes programmed with the latest point-of-care regenerative medicine protocols and follow-up procedures to make it easy for stem cell patients to schedule appointments by phone, and for practitioners to document patient progress and gather important data to establish the safety and efficacy of stem cell treatments in the physician’s office environment.

The StemData system app is marketed exclusively through Global Stem Cells Group and will be provided free of charge to affiliate physicians in the Stem Cell Center network.

StemData’s cloud-based, server-less solution is accessible via web, iPad, iPhone, Google Glass and Apple Watch. Global Stem Cells Group has utilized the development of the latest electronic medical record (EMR) systems to bring intelligent EMR technology to regenerative medicine specialists.

The StemData app helps regenerative medicine practitioners increase efficiencies in their medical practices while improving both treatment and business outcomes. The app will intuitively adapt to each individual practitioner’s unique practice preferences.

To learn more about GSCG’s StemData solution, visit http://www.stemdata.org, email info@stemcellsgroup.com, or call +1305 560 5337.

About Global Stem Cells Group:

stemdata relaunch


Global Stem Cells Group
(GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global Stem Cell Group’s aim is to be the largest recognized stem cell and regenerative medicine network in the world.

stemdata relaunch

ISSCA Buenos Aires

The International Association for Stem Cell Application moved to a new office at Piedra 383 at Ciudad Autonoma of Buenos Aires, Argentina. The move accommodates ISSCA’s increasing specialty and patient volume, as well as its expanding regenerative medicine certification training programs.

MIAMI, Nov. 29, 2017—The International Association for Stem Cell Application (ISSCA) has announced the move of its Puerto Madero office in Buenos Aires to a new location just a few blocks away to Piedra 363. The new location will house an ISSCA regional office and treatment center.

ISSCA Buenos Aires

The move to the larger office reflects ISSCA’s need to accommodate rapidly expanding patient volume and specialty offerings at its Buenos Aires center. The larger clinical and office space will allow ISSCA to continue providing superior services to patients traveling from the U.S, and worldwide for regenerative medicine treatments. The new location includes a dedicated conference room to host ongoing regenerative medicine training programs and more than three new procedure rooms.

ISSCA celebrated the new location’s grand opening Nov. 26-27, 2017, and host ISSCA regenerative medicine certification training courses for physicians.

To learn more about the ISSCA’s Buenos Aires center and training courses, visit the ISSCA website, email info@stemcellsgroup.com, or call 305-560-5337.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.

The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.

As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.  Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

###

ISSCA Buenos Aires

Magellan Autologous

                                                                            Magellan Autologous Platelet Separator

Global Stem Cells Group and its subsidiary Adimarket named representatives for Magellan Autologous Platelet Separator in Latin America and Middle East.

 MIAMI, Nov. 29, 2017— Global Stem Cells Group (GSCG), a world leader in stem cell and regenerative medicine, and its subsidiary Adimarket have been named to represent the Magellan Autologous Platelet Separator in Latin America and Middle East.

Developed by Arteriorcyte Medical Systems, a leading medical device company headquartered in Hopkinton, Mass., the Magellan Autologous Platelet Separator is a high-tech, automated dual spin processing system designed for use in clinical laboratories or intraoperatively at the point-of-care for safe and rapid preparation of high-quality, platelet-rich plasma (PRP) as well as platelet poor plasma (PPP).

Global Stem Cells Group CEO Benito Novas says the Magellan system is a perfect fit for GSCG and Adimarket’s ever-growing list of high-tech regenerative medicine products and equipment, made available to physicians and qualified practitioners through the Adimarket online store.

“We share Arteriocyte’s commitment to research and development of blood component technology to advance treatments that benefit patients in the field of regenerative medicine,” Novas says. “The Magellan system furthers GSCG’s drive to invest in platelet separation technologies that focus on the development of new surgical applications for PRP and elevates these technologies to the next level.”

The fully-automated Magellan system is specifically designed to fractionate blood at bedside without a need for manual manipulation. At the end of its cycle, the Magellan PRP is delivered into a collection syringe, ready for immediate application.

As an industry leader, Adimarket added the Magellan Autologous Platelet Separator System to its online regenerative medicine store to allow physicians to meet the specific needs of each patient with fully customizable product volumes and platelet concentrations. The system can be programmed to deliver a volume of 3 – 10 mL from each processing cycle, allowing practitioners to customize the concentration per mL within the PRP.  The Magellan system is approved for three processing cycles per disposable separation chamber, allowing for a maximum of 30 mL of product.

For more information, visit the Adimarket regenerative medicine online store website, email info@stemcellsgroup.com, or call 305-560-5337.

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global stem cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world.

About Adimarket:

Adimarket, Inc., a division of the Global Stem Cells Group, is a one-stop, cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals.

Adimarket was founded to provide practitioners the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting-edge treatments.

About Arteriorcyte Medical Systems:
Magellan Autologous Platelet Separator
Arteriocyte Medical Systems, Inc. is a leading medical device company committed to developing and marketing novel medical products to help patients heal faster. Established in 2007 by Arteriocyte, Inc. and DW Healthcare Partners, Arteriocyte Medical Systems is devoted to providing innovative solutions to patients and medical professionals to address serious unmet medical needs particularly in cardiac, orthopedic and vascular surgeries.

###

Magellan Autologous platelet separator

ISSCA Miami

ISSCA will conduct the first regenerative medicine certification training course for the upcoming year in Miami Feb. 2-3, 2018. The two-day course focuses on pain management and aesthetic regenerative medicine protocols.

MIAMI, Nov. 20, 2017—The International Society for Stem Cell Application (ISSCA) announced plans to hold its first regenerative medicine certification training course of the upcoming year Feb. 2 – 3, 2018 in Miami.

The two-day, hands-on training course focuses on pain management and aesthetic regenerative medicine protocols. Practitioners learn skills that can be used to treat patients in their practices, and for career advancement. The course provides participating physicians with training in stem cell applications to benefit patients undergoing aesthetic procedures or being treated for specific medical condtions.

Participating physicians will also receive access to the online stem cell training course to review all content and procedures introduced in the 2-day clinical training course, patient forms and guidelines, procedure informed consent forms, didactic lectures, training booklets, and more.

The ISSCA pain management and aesthetic regenerative medicine protocols training course was developed for physicians and high-level practitioners to learn techniques in harvesting and reintegrating stem cells derived from adipose tissue and bone marrow.

Stem cell therapies continue to revolutionize the anti-aging aesthetics industry and help improve the quality of life for patients suffering from some chronic conditions.

To learn more about the training course and register to participate, visit the Stem Cell Training Course website, email info@stemcellsgroup.com, or call 305-560-5337.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.

The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.

As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.  Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

 

Cidranes ISSCA

 

Ernesto Miguel Delgado Cidranes, M.D., Ph.D., appointed regional director of ISSCA chapter in Europe.

MIAMI, Nov. 22, 2017—International Society for Stem Cell Application (ISSCA) President Daeyong Kim, Ph.D., has named Ernesto Miguel Delgado Cidranes, M.D., Ph.D., Regional Director of the ISSCA chapter in Europe.

Cidranes is an anesthesiologist and resuscitation and intensive care specialist in, Madrid, Spain. He is a renowned expert in pain management and promotes an integrative and interdisciplinary approach to the treatment of pain. Cidranes’s areas of expertise include interventional pain management, pain treatment, stem cell therapies, and regenerative medicine.

As the European regional director, Cidranes will promote ISSCA activities in EU, and collaborate with the organization to establish new standards for regenerative medicine protocols worldwide. Cidranes will conduct a specialized training workshop in pain management and cosmetic gynecology Feb. 25-26, 2018 in Madrid, Spain, and plans to promote the workshop throughout Europe.

He is director, CEO, and founder at Advanced Pain and Aesthetic Management Center in Madrid, and serves on the advisory board for ISSCA affiliate Global Stem Cells Group. Cidranes is also head of service at the La Milagrosa Hospital Pain Unit and the Pain Unit Los Madronas Hospital, both in Madrid.

He serves as a medical specialist in anesthesiology-reanimation and pain therapy at the Hospital Ramon y Cajal in Madrid, and an editorial board member of the Journal Pain Management and Therapy. Cidranes is also a popular international speaker on pain management, stem cell therapies, regenerative medicine, and ultrasound techniques.

“It is a pleasure to have Dr. Cidranes representing ISSCA in Europe, and as a collaborator in our efforts to establish new regenerative medicine standards worldwide,” He brings a wealth of experience and expertise to the ISSCA organization.”

To learn more about ISSCA, visit the stemcellglobal.org website, email info@stemcellsgroup.com, or call +1305 560 5337.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.

The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.

As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.  Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

 

human stem cells

Scientists from the U.K. and Sweden have discovered a new method of creating human stem cells that could solve the problem of meeting large-scale production needs, allowing researchers to fully realize the potential of stem cells for understanding and treating disease.

Human pluripotent stem cells are undifferentiated cells that have the unique potential to develop into all the different types of
cells in the body. With applications in disease modeling, drug screening, regenerative medicine and tissue engineering, there is already an enormous demand for these cells, and that demand will continue grow as their use in clinical settings and the pharmaceutical industry increases.

Human embryonic stem cell line HUES1 grown in the new conditions E8+Inter-alpha-inhibitor and imaged for stem cell marker Oct4 (green) and cell-cell attachment molecule E-cadherin (red) with nuclear counter-staining (blue). Credit: Dr. Sara Pijuan-Galito and Dr. Cathy Merry, Wolfson Centre for Stem Cells, Tissue Engineering & Modelling and Centre for Biomolecular Sciences, The University of Nottingham Read more at: http://phys.org/news/2016-07-breakthrough-scaling-life-changing-stem-cell_line

Human embryonic stem cell line HUES1 grown in the new conditions E8+Inter-alpha-inhibitor and imaged for stem cell marker Oct4 (green) and cell-cell attachment molecule E-cadherin (red) with nuclear counter-staining (blue).
Credit: Dr. Sara Pijuan-Galito and Dr. Cathy Merry, Wolfson Centre for Stem Cells, Tissue Engineering & Modelling and Centre for Biomolecular Sciences, The University of Nottingham.

However, production of stem cells at the scale required for optimal application in modern research and healthcare has not beenfeasible because available culture methods are either too expensive, or reliant on substances that would not be safe for clinical use in humans.

The research results, published in Nature Communications in July, describe how the scientific team from The University of Nottingham’s Wolfson Centre for Stem Cells, Tissue Engineering and Modelling at Uppsala University in Sweden and GE Healthcare also in Sweden have identified and improved human stem cell culture methods that could lead to quicker and cheaper large scale industrial production of human pluripotent stem cells.

By using a protein derived from human blood called Inter-alpha inhibitor, the team has grown human pluripotent stem cells in a minimal medium without the need for costly and time-consuming biological substrates. Inter-alpha inhibitor is found in human blood at high concentrations, and is currently a by-product of standard drug purification schemes.

The human serum-derived protein can make stem cells attach to unmodified tissue culture plastic, eliminating the need for coating in defined human pluripotent stem cell culture, and improving survival capabilities of the stem cells in harsh conditions.

It is the first stem cell culture method that does not require a pre-treated biological substrate for attachment, and therefore, is more cost and time efficient, paving the way for easier and cheaper large-scale production.

Existing methods are time consuming and make developing human stem cell cultures prohibitively costly. This new method has the potential to save time and money in large-scale and high-throughput cultures, and be highly valuable for both basic research and commercial applications.

The work began at Uppsala University, and the study’s first author, Sara Pijuan-Galitó PhD., is continuing her work as a Swedish Research Council Research Fellow at Nottingham.

Researchers now intend to combine Inter-alpha inhibitor protein with an innovative hydrogel technology to improve on current methods for controlling cell differentiation, and also apply it to disease modelling. The discovery, according to the findings, will help facilitate research into many diseases although their focus is currently on understanding rare conditions like Multiple Osteochondroma) at the cellular level. The aim is to replicate the 3 dimensional environment that cells experience within the body so that lab-bench biology is more accurate in modelling diseases.

Pijuan-Galitó has been awarded the Sir Henry Wellcome Postdoctoral Fellowship at Nottingham University for her work on the research, which will enable her to combine Inter-alpha inhibitor with improved synthetic polymers in collaboration with fellow regenerative medicine pioneers Professor Morgan Alexander and Professor Chris Denning. The team plans to further improve on current human stem cell culture by designing an economical and safe method that can be easily translated to large-scale production and can deliver billions of stem cells necessary move cellular therapeutics forward in patient settings.

The study, titled “Human serum-derived protein removes the need for coating in defined human pluripotent stem cell culture,” was published in Nature Communications in July, 2016.

###

stem cell training certification

MIAMI, Sept. 13, 2016-Global Stem Cells Group announced plans to hold a stem cell training certification course Oct. 1 -2, 2016 following the 3rd annual Global Stem Cells Group International Symposium on Stem Cells and Regenerative Medicine in Buenos Aires. The symposium will take place Sept. 28, 2016.

The two-day, hands-on training course covers the latest technology and procedures in SVF and bone marrow stem cell techniques. Practitioners learn skills that can be used to treat patients in their practices, and for career advancement. The SVF and bone marrow aspiration course was developed for physicians and high-level practitioners to learn techniques in harvesting and rein

stem cell training certification

Joseph Purita, MD

tegrating stem cells derived from adipose tissue and bone marrow. The objective of the training teach effective, in-office regenerative medicine techniques.

stem cell training certification

Silvina Pastrana, M.D.

The course will be taught by GSCG Advisory Board members Joseph Purita, M.D. and Silvina Pastrana, M.D.

The stem cell training certification course will be held at the Global Subsidiary Stem Cell Center Network in Puerto Madero Buenos Aires immediately following the 3rd annual International Symposium on Stem Cells and Regenerative Medicine.

Since 2014, Global Stem Cells Group has joined forces with some of the most prestigious regenerative medicine practitioners in South America as it focuses on growing its services throughout the global community. Stem cell therapies continue to revolutionize the anti-aging aesthetics industry and help improve the quality of life for patients suffering from some chronic conditions.

To learn more about the 3rd Annual International Symposium on Stem Cells and Regenerative Medicine, visit the Global Stem Cells Group website, email bnovas(at)stemcellsgroup(dot)com, or call 305-560-5337.
stem cell training certification
About Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

To view this press release live online, click here

###